8-K: OrthoPediatrics Cuts 2025 Revenue Outlook Amid Sales Delays

OrthoPediatrics Corp. announced preliminary third-quarter 2025 revenue and revised its full-year 2025 financial guidance downwards due to delayed capital and international sales.

Summary

• Preliminary unaudited third quarter 2025 net revenue reached approximately $61.2 million, a 12% increase compared to $54.6 million in Q3 2024.
• Domestic net revenue for Q3 2025 was approximately $48.7 million, growing 14% year-over-year.
• International net revenue for Q3 2025 was approximately $12.5 million, growing 6% year-over-year, impacted by timing of set sales and large stocking orders in Latin and South America.
• Net revenue excluding 7D capital sales for Q3 2025 was approximately $60.7 million, representing 17% growth compared to $51.8 million in Q3 2024.
• Full-year 2025 revenue guidance was revised to $233.5 million to $234.5 million, down from the previous range of $237.0 million to $242.0 million.
• The revised guidance still represents 14% to 15% growth over 2024 revenue.
• The company reiterated its expectation for annual set deployment at $15.0 million and adjusted EBITDA guidance of $15.0 million to $17.0 million for full-year 2025.
• OrthoPediatrics has helped over 37,100 children in Q3 2025, bringing the total to approximately 1.3 million children since inception.

Sentiment

Score: 4

Explanation: While the company reported positive Q3 revenue growth, the significant downward revision of full-year guidance due to ongoing issues with capital equipment and international sales timing indicates a negative shift in short-term expectations. The reiteration of EBITDA and set deployment provides some stability, but the revenue cut is a clear negative signal.

Positives

• Achieved preliminary unaudited third quarter 2025 net revenue of approximately $61.2 million, representing 12% growth year-over-year.
• Domestic net revenue grew 14% in Q3 2025 to approximately $48.7 million.
• Net revenue excluding 7D capital sales grew 17% in Q3 2025 to approximately $60.7 million.
• Domestic net revenue excluding 7D capital sales grew 19% in Q3 2025 to approximately $48.2 million.
• Reiterated annual set deployment expectation of $15.0 million.
• Reiterated adjusted EBITDA guidance range of $15.0 million to $17.0 million for full-year 2025.
• Helped over 37,100 children in Q3 2025, contributing to a total of approximately 1.3 million children since inception.
• Management reaffirmed commitment to driving revenue growth, expanding profitability, and achieving cash flow break-even in 2026.

Negatives

• Full-year 2025 revenue guidance was decreased to $233.5 million $234.5 million from the previous range of $237.0 million $242.0 million.
• International net revenue growth of 6% in Q3 2025 was negatively impacted by the timing of set sales and large stocking orders in Latin and South America.
• Experienced incremental headwinds late in September, largely driven by delayed 7D capital sales.
• Management believes it is prudent to reflect minimal sales growth from 7D capital sales and Latin and South America segments for the fourth quarter and into the future due to variable and difficult-to-forecast order timing.

Risks

• Uncertainty in timing of 7D capital sales.
• Uncertainty in timing of Latin and South America set sales and stocking orders.
• Risks related to widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and their impact on product demand.
• General risks, uncertainties, and factors set forth under "Risk Factors" in OrthoPediatrics' Annual Report on Form 10-K filed with the SEC on March 5, 2025, and other SEC reports.
• Preliminary unaudited net revenue estimates are subject to adjustment upon completion of review and audit procedures.
• Actual results for Q3 2025 and full-year 2025 could differ materially from preliminary estimates and forecasted amounts.

Future Outlook

The company revised its full-year 2025 revenue guidance downwards to $233.5 million to $234.5 million, citing uncertainty in the timing of 7D capital sales and international set sales, particularly in Latin and South America. Management expects minimal sales growth from these segments for the fourth quarter and into the future due to their variable and difficult-to-forecast nature. Despite this, OrthoPediatrics reiterated its annual set deployment of $15.0 million and adjusted EBITDA guidance of $15.0 million to $17.0 million for 2025. The company remains committed to driving revenue growth, expanding profitability, and achieving cash flow break-even in 2026.

Management Comments

• "In the third quarter, we faced incremental headwinds late in September, largely driven by delayed 7D capital sales and headwinds within the Latin and South America segment of our business, which contributed to a revenue shortfall relative to our expectations."
• "While still important parts of our business plan, order timing across these segments is difficult to forecast and will continue to be variable. We believe it is prudent to reflect minimal sales growth from these segments for the fourth quarter and into the future."
• "We are reaffirming a steadfast commitment to driving revenue growth that expands profitability and supports achieving cash flow break-even in 2026."
• "Our comprehensive product portfolio, including OPSB braces and services, combined with the breadth of our commercial footprint uniquely positions OrthoPediatrics as the undisputed leader in pediatric orthopedics, will enable the organization to execute on our mission to continue to help more kids every year."

Industry Context

OrthoPediatrics operates exclusively in the specialized and growing field of pediatric orthopedics, a niche market within the broader medical device industry. The company's focus on a comprehensive product offering for trauma and deformity, scoliosis, and sports medicine/other procedures positions it as a leader. The challenges faced with 7D capital sales and international stocking orders highlight the inherent variability and longer sales cycles often associated with high-value medical equipment and international distribution, which can be susceptible to regional economic conditions and healthcare spending priorities. Despite these specific headwinds, the company's continued overall revenue growth and commitment to profitability and cash flow break-even in 2026 suggest resilience in its core market.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to reduced revenue guidance, but some reassurance from reiterated EBITDA and long-term commitment to profitability.
• Customers (Children/Patients): Continued benefit from the company's products, with over 37,100 children helped in Q3 2025.
• Employees: No direct impact mentioned, but potential for increased pressure to meet revised targets.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned, but the commitment to cash flow break-even in 2026 is a positive for long-term financial health.

Next Steps

• Host a conference call on October 9, 2025, at 4:30 p.m. ET to discuss preliminary results.
• Release full third quarter 2025 financial results and host a conference call after market close on October 28, 2025.
• Work towards achieving cash flow break-even in 2026.

Key Dates

Recommendation

The downward revision of full-year revenue guidance is a clear negative, indicating a slowdown in key segments like 7D capital sales and Latin American markets. While Q3 revenue growth was still positive, the reduced outlook suggests near-term headwinds. However, the company reiterated its Adjusted EBITDA guidance and commitment to cash flow break-even in 2026, indicating underlying operational stability and a long-term strategic focus. Given the mixed signals – a revenue cut but stable profitability outlook and a strong market position in pediatric orthopedics – a 'hold' recommendation is prudent. Investors should monitor the full Q3 results on October 28, 2025, and management's commentary for further clarity on the duration and impact of these headwinds before making significant changes to their position.

Keywords

OrthoPediatrics, KIDS, pediatric orthopedics, medical devices, SEC filing, revenue guidance, Q3 2025 results, financial outlook, 7D capital sales, international sales, adjusted EBITDA, orthopedic implants, trauma and deformity, scoliosis, sports medicine